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Purpose. To study the effect of duodenal-jejunal omega switch (DJOS) in combination with different dietary patterns on the retinol-
binding protein (RBP4), fetuin-A, and fibroblast growth factor 21 (FGF21) plasma levels and their hepatic gene expressions in rats.
Methods. A high-fat diet (HF) was given to 28 rats and 28 more were fed with a control diet (CD) for 2 months. After that, half
of each group underwent either DJOS or SHAM surgery. For the next 2 months, half of the animals in each operation group were
kept on the same diet as before and half of them had the diet changed. After 16 weeks of the experiment RBP4, fetuin-A, and FGF21
plasma levels as well as liverRbp4,Ahsg, and Fgf21 gene expressions weremeasured.Results. DJOS had a reductive impact on plasma
levels of RBP4, fetuin-A, and FGF21 and Rbp4, Ahsg, and Fgf21 relative gene expression in the liver when compared to SHAM.The
HF/HF group expressed significantly higher RBP4 and fetuin-A plasma levels in comparison to the control.TheHF diet used before
and/or after surgery led to upregulation of Rbp4, Ahsg, and Fgf21 relative gene expression.The lowest levels of analyzed parameters
were observed in the CD/CD group. Conclusions. The efficiency of DJOS surgery, measured by hepatokines’ plasma levels and their
gene expressions in the liver, depends on the type of diet applied before and after surgery. Manipulation of dietary patterns can lead
to marked improvements in metabolic profile after DJOS surgery.
1. Introduction
Overconsumption of any form of dietary energy leads to
overweight, obesity, diabetes mellitus type 2 (T2DM), and
related comorbidities [1–3].
The studies of the effect of metabolic surgery focus
broadly on the general health improvement [4]. A ret-
rospective cohort study of patients with T2DM who had
undergone RYGB surgery showed that 70% of the patients
experienced a complete remission in the first 5 years, but
among these 35% developed T2DM within 5 years after
remission. Secretory proteins released from the liver, called
hepatokines, are related to the development of impaired
glucose and lipid metabolism. RBP4 acts as a negative acute
phase inflammatory protein and contributes to systematic
insulin resistance; it is upregulated in patients with obesity
and T2DM [5]. Enhanced expression of the Rpb4 gene is
correlated with increased risk of T2DM and may be one of
triggering factors for the disease development [6]. Plasma
retinol-binding protein (RBP4) and its overexpression is a
Hindawi
BioMed Research International
Volume 2018, Article ID 3472190, 11 pages
https://doi.org/10.1155/2018/3472190
2 BioMed Research International
biomarker for insulin resistance, prediabetes and T2DM,
the metabolic syndrome, and myocardial infarction [7–
10]. Fetuin-A enhances lipid accumulation and activates
inflammatory signalling in the liver. This protein is involved
in the regulation of postprandial glucose disposal, insulin
sensitivity, weight gain, and fat accumulation [11]. A sig-
nificant increase in fetuin-A (Ahsg) gene expression has
been observed in an animal diet-induced obesity model
[12]. Finally, the hepatic fibroblast growth factor 21 (FGF21)
enhances lipid oxidation and lipolysis, suppresses hepatic
steatosis, and decreases obesity-induced insulin resistance
[11].
DJOS is a type of bariatric surgery, with proximal
loop duodenoenterostomy, which bypasses the foregut and
directly stimulates the hindgut [13]. The advantage of DJOS
is that the pylorus of the patients stays intact, which reduces
symptoms characteristic for postgastrectomy conditions such
as dumping, diarrhoea, and dyspepsia [14, 15]. DJOS is a
relatively new technique; thus an animal model, for exploring
the physiological, long-term effects of this procedure, is still
needed [14–16]. The aim of this work was to study the effi-
ciency of duodenal-jejunal omega switch (DJOS) in relation
to different dietary patterns, measured by the retinol-binding
protein (RBP4), fetuin-A, and fibroblast growth factor 21
(FGF21) plasma levels and their hepatic gene expressions in
rats. Nutrient rich diet and bariatric surgery may strongly
stimulate hepatokines’ metabolic pathways, levels, and activ-
ity [17, 18]. Thus, the diet combinations used were intended
to imitate various dietary behaviours of patients, both before
and after the surgery. As the liver plays a major role in the
regulation of systemic glucose metabolism, which may result
in impaired systemic glycaemic control and the development
of T2DM,we focused on liver function andmeasured the liver
gene expression of Rbp4, Ahsg, and Fgf21 [17]. We studied
applied dietary patterns and selected hepatokines in relation
to duodenal exclusion surgery, which is becoming one of the
popular bariatric procedures. Finally, we studied the ability
of different dietary patterns to influence RBP4, fetuin-A, and
FGF21 plasma levels and their liver gene expressions.
2. Materials and Methods
2.1. Animals. Seven-week-old male Sprague-Dawley rats
were acquired from Charles River Breeding Laboratories
(Wilmington, Mass.). Animal care was performed according
to previously described procedures [19]. Animals were kept
in with 12 h light-dark cycles at 22∘C and 40–60% humidity.
Environmental enrichment was provided, and all rats had
free access to water and food. The composition of control
diet (CD) was as follows: 24% protein, 4.9% fat, 7% crude
ashes, and 4.7% crude fiber (Provimi Kliba AG, Kaiseraugst,
Switzerland). The animals from control group were kept on
CD for the period of two months, before and after surgery.
Obesity was induced by keeping the animals on a high-fat
diet (HF; 23.0 kJ/g; 59% fat, 27% carbohydrate, and 14%
protein (Ssniff Spezialdia¨ten GmbH, Soest, Germany)) for
the period of two months before and after surgery. Full
description of diets used in the experiment is presented in
the supplementarymaterials (supplementary Table 1). All rats
fasted overnight before surgery. All experimental procedures
were approved by the Local Ethics Committee (58/2014). All
applicable institutional and/or national guidelines for the care
and use of animals were followed (EUDirective 2010/63/EU).
2.2. Experimental Design. The experimental design of the
study was conducted accordingly to previously reported
methodology [19]. Briefly, two types of diet, control diet (CD)
and high-fat diet (HF), were applied before surgery for 8
weeks (Figure 1(a)). After surgery, half of the animals from
the CD and HF groups had the diet changed (Figure 1(a)).
The number of animals included in the study was kept as
small as possible in consideration of the “3Rs” for the humane
treatment of animals [20]. The numbers of rats that survived
till the end of the experiment in the experimental groupswere
7, except for the HF/SHAM/CD where 6 rats survived.
A DJOS was performed according to Karcz et al.
methodology [16] previously described [19]. Rats were fasted
overnight before the surgery. Surgerieswere performedunder
general anaesthesia with 2% isoflurane (AbbVie Deutschland
GmbH&Co. KG, Ludwigshafen, Germany) and oxygen flow
at 2 l/min under spontaneous breathing. Analgesia was per-
formed with xylazine (5 mg/kg b.w., ip; Xylapan, Vetoquinol
Biovet, Poland) and antibiotic prophylaxis with gentamicin
(5mg/kg b.w., im). The DJOS and SHAM surgeries have
been previously described [19]. After a midline incision of
3–4 cm to gain abdominal access, the total length of the
small intestine was measured. The duodenoenterostomy was
located approximately at 30% of the total small bowel length
(Figure 1(b)). The earlier defined jejunum was anastomosed
by end-to-side duodenoenterostomy in order to restore
continuity, excluding the duodenum and parts of the small
intestine bowel.The stump of the duodenum was closed with
cross suture (Prolene 6/0, Ethicon). For the SHAM surgery,
transections and reanastomosis were made and closed using
PDS 6/0 (Ethicon) in the duodenum and small intestine
(Figure 1(c)). Fascia and skin closure were performed using
Monocryl 4/0 and Vicryl 4/0.
2.3. Tissue Collection and Assays Identification. Before
surgery, reference biopsies of liver tissue were collected,
rinsed with PBS, and placed into RNAlater RNA Stabilization
Reagent (Qiagen, Hilden, Germany). The samples were
subsequently snap frozen to –80∘C and kept at this
temperature for 3 months until Rbp4, Ahsg, Fgf21 gene
expression analyses were performed.
Eight weeks after surgery, blood for hepatokines’ analysis
was collected from the abdominal aorta into tubes containing
10 𝜇l of EDTA (Sigma-Aldrich, St. Louis, Mo, USA). After
centrifugation at 4 000 rpm for 10 minutes at 4∘C, plasma
samples were collected and snap frozen in liquid nitrogen and
stored at – 80∘C until analysis was performed. Hepatokines,
such as RBP4, fetuin-A, and FGF21, were assessed in duplicate
by ELISA kits (Cloud-Clone Corp., Katy, Tex., USA).
After blood sampling the tissues were harvested and
the animals were euthanized. Liver tissue was explanted,
rinsed with PBS, and placed into RNAlater RNA Stabilization
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Figure 1: (a) Scheme of experimental groups. (b) Schematic illustrations of duodenal-jejunal omega switch (DJOS) and (c) SHAM surgery.
Reagent (Qiagen,Hilden, Germany).Then samples were snap
frozen at –80∘C for 1 month until further analysis.
2.4. Gene Expression. The liver tissues were taken from
animals of all the experimental groups before (control tis-
sue) and after DJOS and SHAM surgery (test tissue). The
tissues were homogenised (Lysing Matrix D 1,4 mm ceramic
spheres, FastPrep-24 Classic Instrument, MP Biomedicals,
Santa Ana, CA, USA) in excess of TRI Reagent (Sigma-
Aldrich, Saint Louis, Mo, USA), and subsequently RNA
was isolated according to the manufacturer’s instructions.
RNA concentration was measured with a DS-11 microvolume
spectrophotometer (DeNovix, Wilmington, DE, USA). RNA
integrity was determined by a Lab-on-a-Chip capillary elec-
trophoresis system (RNA 6000 Nano Kit, 2100 Bioanalyzer
Instruments and 2100 Expert Software, Agilent Genomics,
Santa Clara, CA, USA). RNA Integrity Number (RIN) > 7
samples was used for further study. Residual DNA contam-
ination was removed by DNase I (Worthington Biochemical
Corporation, Lakewood, NJ, USA) treatment. After thermal
inactivation of the enzyme, cDNA was synthesized from
200 ng of total RNA by SuperScript IV VILO Master Mix
(Invitrogen, Thermo Fisher Scientific, Wilmington, USA);
in parallel, no RT control reaction was conducted for each
RNA sample. The STA (Single Tube TaqMan Gene Expres-
sion Assay) assays were as follows: Ahsg (Rn00563700 m1),
Fgf21 (Rn00590706 m1), Rbp4 (Rn01451318 m1), and Slc2a4
(Rn00562597 m1); reference STA assays were as follows:
Pum1 (Rn00982780 m1), Rpl37a (Rn02114291 s1), and Tbp
(Rn01455648 m1); TaqMan Universal PCR Master Mix and
ViiA 7 Real-Time PCR System (Thermo Fisher Scientific,
Waltham, MA USA) were used for quantitative real-time
PCR, which was performed in the 96-well format with
an epMotion 5070 liquid handling workstation (Eppendorf,
Hamburg, Germany). Four microliters of diluted (1:80)
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cDNA or no RT control sample was used in each PCR
reaction; all reactions were performed in triplicate according
to the original STA assay manufacturer’s protocol, with a
minor modification (10 𝜇l reaction volume). In the STA, no
PCRamplificationwas detected for the noRT control samples
before cycle number 40. Gene expression was determined
with the ΔΔCq method. Normalisation was performed to a
reference index obtained by calculating the geometric mean
of reference gene (Pum1, Rpl37a, and Tbp) expression. The
fold change of analyzed gene expression level was calculated
as a difference between normalised values obtained from the
same animal before and after surgery.
2.5. Statistical Analysis. Statistical analysis was performed
using STATISTICA 12.5 PL (StatSoft, Cracow, Poland). Sta-
tistical significance was set at a p value below 0.05. All tests
were two-tailed. Interval data were expressed as mean value
± standard deviation in the case of normal distribution or as
median/lower–upper quartile range in the case of data with
skewed or nonnormal distribution. Distribution of variables
was evaluated by the Shapiro-Wilk test and the quantile-
quantile plot- homogeneity of variances was assessed by the
Levene test. For comparison of data, the two-way parametric
ANOVA with post hoc contrast analysis or nonparametric
Kruskal-Wallis test or theUMann-Whitney test were used. In
case of skewed data distribution, logarithmic transformation
was done before analysis.
3. Results
The results of body weight change after DJOS and SHAM
surgery in all experimental groups were presented in our
previous study [19]. Briefly, DJOS surgery was shown to
have very little impact on body weight reduction. In the
DJOS groups, the body weight had no negative effect on
insulin levels, glucose tolerance, or liver fat deposition.
After DJOS, even though the body weight increased, the
amelioration of glucose tolerance was reached for the HF/HF
and CD/CD groups, but not for the mixed diet groups
(HF/CD and CD/HF). Changes in diet after surgery influ-
enced the glucose stimulated insulin secretion. After DJOS
surgery, the glucose tolerance was ameliorated in both the
HF/HF and CD/CD groups, but not in the groups of
animals whose diet was changed from a HF to a CD and
from a CD to a HF. The glucose amelioration in HF/HF
subjects was found to be comparable with the control
group, which can be an effect of ketogenic properties of a
HF.
Table 1 shows the measured plasma concentrations of
RBP4, fetuin-A, and FGF21 and the Rbp4, fetuin-A (Ahsg),
and Fgf21 gene expression in the liver of animals that had
been subjected to DJOS and SHAM surgery. For most of
the analyzed hepatokines, their plasma concentrations were
higher after DJOS surgery when a comparison between
surgery and type of diet used was conducted. Table 1 also
shows differences in gene expression of Rbp4,Ahsg, and Fgf21
in the liver tissues of animals after both types of surgery.
Significant differences in gene expressions were deduced
from two-way ANOVA analysis between type of surgery,
groups, and interaction between group and operation type.
When the two-way analysis of variance showed that one
of the main analyzed factors is statistically significant and
when also, but not necessarily, interaction between two main
factors occurs, then contrast analysis can be performed.
It means that we can compare each subclass of the first
factor between groups defined by the first factor (p value
for comparisons between types of operation, SHAM and
DJOS) and each subclass of the second factor between groups
defined by the first factor (p value for comparisons between
diets, i.e., HF/HF, HF/CD, CD/HF, and CD/CD). Multiple
comparisons in contrast analysis of hepatokines plasma levels
in DJOS and SHAM operated groups in relation to diet
used before and after surgery are presented in Table 2.
Column one shows a comparison between DJOS and SHAM
surgery associated with different diets, column two shows
comparisons between dietary groups of DJOS animals, and
column three shows comparisons between dietary groups of
SHAM animals.
3.1. RBP4 Plasma Levels
3.1.1. DJOS vs. SHAMSurgery. DJOS surgery had a significant
reductive impact on the RBP4 plasma levels in the groups
of animals kept on HF/HF and HF/CD, when compared to
SHAM surgery (Figure 2(a), Table 1 (general comparison),
and Table 2 (multiple comparisons)).
3.1.2. DJOS Surgery. Plasma concentrations of RBP4 were
significantly higher inHF/HF groupwhen compared to other
studied groups (Figure 2(a); Tables 1 and 2). In the groups
maintained on mixed diet (HF/CD and CD/HF) the level
of RBP4 was significantly higher in comparison to CD/CD
group (Figure 2(a), Table 2).
3.1.3. SHAM Surgery. The same trend in RBP4 plasma levels
as for DJOS surgery was observed for SHAM operated
animals (Figure 2(a), Table 2).
3.2. Rbp4 Expression
3.2.1. DJOS vs. SHAM Surgery. Type of surgery, diet, and
interaction between group and operation type had significant
impact on the Rbp4 liver expression (Table 1). Significantly
higher expression of Rbp4 was observed in animals main-
tained on HF/HF and CD/HF after SHAM surgery when
compared to DJOS (Figure 2(b); Tables 1 and 2).
3.2.2. DJOS Surgery. A higher expression of Rbp4 gene was
observed in the groups of animals kept on HF/HF, HF/CD,
andCD/HF as comparedwith theCD/CDgroup (Figure 2(b);
Tables 1 and 2). Rbp4 gene expression was also significantly
stronger in theHF/HF than in theHF/CDgroup (Figure 2(b);
Tables 1 and 2).
3.2.3. SHAM Surgery. Similar differences in Rbp4 gene
expression as in the DJOS surgery were observed in SHAM
BioMed Research International 5
Table 1: Plasma levels of RBP4, fetuin-A, FGF21, and fold change of Rbp4, FetuinA (Ahsg), and Fgf21 in liver tissue 8 weeks after DJOS (1st
column) and SHAM (2nd column) surgery, subjected to 16 weeks of different dietary patterns, and intergroup comparison between DJOS and
SHAM study groups (3rd column) using descriptive statistics and results of two-way analysis of variance.
DJOS SHAM p ANOVA
Parameter HF/HF HF/CD CD/HF CD/CD HF/HF HF/CD CD/HF CD/CD Group Op. Int.
Plasma levels
RBP-4
[ng/mL] 61.1 ± 10.4
40.5 ±
10.0
44.8 ±
10.2 11.5 ± 3.2 79.6 ± 11.7
54.4 ±
12.2 49.6 ± 21.1 17.7 ± 4.2 <0.001 <0.01 0.377
Fetuin-A
[ng/mL] 12.6 ± 2.3 10.6 ± 4.9 11.4 ± 1.3 5.8 ± 2.2 16.2 ± 1.1 15.9 ± 1.5 14.0 ± 1.0 10.3 ± 1.7 <0.001 <0.001 0.498
FGF 21
[ng/mL]
304.8 ±
195.3
332.2 ±
285.5
442.3 ±
254.8
269.3 ±
139.5
772.9 ±
98.3
772.7 ±
74.1
721.1 ±
136.4
387.5 ±
130.8 <0.01 <0.001 <0.05
Fold change
RBP-4 1.26 ± 0.12 1.00 ±0.08 1.17 ± 0.14
0.50 ±
0.09 1.57 ± 0.17
1.24 ±
0.23
1.74 ±
0.43
0.65 ±
0.22 <0.001 <0.001 <0.05
Fetuin-A
(Ahsg)
1.60 ±
0.22 1.20 ± 0.21
0.58 ±
0.18
0.33 ±
0.10
2.94 ±
0.60
1.96 ±
0.34
1.46 ±
0.09
0.59 ±
0.19 <0.001 <0.001 <0.001
FGF 21 4.37 ±0.55
4.44 ±
0.29
4.57 ±
0.40
1.07 ±
0.35
5.80 ±
0.40 5.31 ± 0.93 4.69 ± 1.14 1.11 ± 0.40 <0.001 <0.001 <0.01
Statistical significance was set at a p < 0.05. Abbreviations: RBP4: retinol binding protein 4; FGF21: fibroblast growth factor 21. DJOS: duodenal-jejunal omega
switch surgery; HF: high-fat diet; CD: control diet; HF/HF, CD/HF, HF/CD, and CD/CD: type of diet 8 weeks before/8 weeks after surgery; Op.: operation
type; Int.: interaction between group and operation type. Mean ± standard deviation or median (lower – upper quartile).
Vertical lines depict 95% conﬁdence interval
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Figure 2: (a)Mean values of RBP4 plasma levels in groups subjected to different dietary patterns, according to theDJOS and SHAMoperation
type. Statistical significance was set at p < 0.05. Abbreviations: DJOS: duodenal-jejunal omega switch surgery; HF: high-fat diet; CD: control
diet; HF/HF, CD/HF, HF/CD, and CD/CD: type of diet 8 weeks before/8 weeks after surgery. (b) Mean values of Rbp4 fold change between
groups subjected to different dietary patterns, according to the DJOS and SHAM operation type.
operated animals exposed to HF/HF and mixed diet before
and after surgery as compared with the CD/CD group
(Figure 2(b); Tables 1 and 2). Significant differences were
also observed between the HF/CD and HF/HF as well as the
HF/CD and CD/HF groups.
3.3. Fetuin-A Plasma Levels
3.3.1. DJOS vs. SHAM Surgery. Significant differences in
fetuin-A plasma concentrations between DJOS and SHAM
groups were found for HF/HF, HF/CD, and CD/CD groups
(Figure 3(a), Tables 1 and 2). In those groups fetuin-A levels
were significantly lower in animals which underwent DJOS
surgery as compared to SHAM surgery.
3.3.2. DJOS Surgery. The lowest plasma level of fetuin-A
was observed in the CD/CD group in comparison to the
HF/HFgroup andmixed diets (HF/CD,CD/HF) (Figure 3(a),
Table 2).
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Figure 3: (a) Mean values of fetuin-A plasma levels in groups of different dietary patterns, according to the DJOS and SHAM operation
type. Statistical significance was set at p < 0.05. Abbreviations: DJOS: duodenal-jejunal omega switch surgery; HF: high-fat diet; CD: control
diet; HF/HF, CD/HF, HF/CD, and CD/CD: type of diet 8 weeks before/8 weeks after surgery. (b) Mean values of Ahsg (fetuin-A) fold change
between groups subjected to different dietary patterns, according to the DJOS and SHAM operation type.
3.3.3. SHAM Surgery. In the SHAM operated animals, the
CD/CD group showed a significantly lower fetuin-A plasma
level as compared with other studied groups (Figure 3(a),
Table 2).
3.4. Fetuin-A Gene Expression (Ahsg)
3.4.1. DJOS vs. SHAMSurgery. TheDJOS and SHAMsurgery,
diet, and interaction between group and operation type had
significant impact on the Ahsg liver expression (Table 1).
The relative expression of the fetuin-A gene in the liver of
DJOS operated animals was significantly lower compared
with SHAM operated groups (Figure 3(b), Tables 1 and 2).
3.4.2. DJOS Surgery. The Ahsg expression in DJOS operated
animals was higher in the group kept on a HF diet before and
after the surgery as compared with other groups (Figure 3(b),
Tables 1 and 2). Mixed type of diet before and after the
surgery (HF/CD) showed significantly higher relative Ahsg
expression when compared to the CD/HF and CD/CD
groups (Figure 3(b), Tables 1 and 2).
3.4.3. SHAM Surgery. The Ahsg mRNA levels significantly
varied among all the studied groups after SHAM surgery. Sig-
nificantly higher values were observed in the HF/HF group
when compared to the HF/CD, CD/HF, and CD/CD animals
(Figure 3(b), Tables 1 and 2). The mixed dietary patterns
(HF/CD and CD/HF) stimulated an enhanced expression
of Ahsg when compared to the CD/CD group (Figure 3(b),
Tables 1 and 2). For the mixed diet groups, Ahsg expression
in the liver tissue was shown to be significantly higher in the
HF/CD group than the CD/HF animals (Figure 3(b), Tables 1
and 2).
3.5. FGF 21 Plasma Levels
3.5.1. DJOS vs. SHAM. In DJOS and SHAM groups an
interaction between group and operation type was observed.
Significant differences between DJOS and SHAM type of
surgery independently to the diet, in the analyzed groups,
were observed (Table 1). Rats which underwent DJOS surgery
showed a significantly lower plasma concentration of FGF
21 than SHAM operated animals in the HF/HF, HF/CD, and
CD/HF diet groups (Figure 4(a), Tables 1 and 2).
3.5.2. DJOS Surgery. There were no significant differences in
FGF 21 plasma concentration between the DJOS operated
animals (Figure 4(a), Tables 1 and 2).
3.5.3. SHAM Surgery. Among SHAM operated animals, the
HF/HF, HF/CD, and CD/HF diet groups exhibited similar
FGF 21 levels as the DJOS operated rats; these concentrations
were significantly higher than in the CD/CD group (Fig-
ure 4(a), Table 2).
3.6. Fgf21 Gene Expression
3.6.1. DJOS vs. SHAM Surgery. Fgf21 gene expression was
significantly different in relation to DJOS and SHAM type
of procedure (Table 1). Diet and interaction between group
and operation type had significant impact on the Fgf21 liver
expression (Table 1). Comparing DJOS and SHAM type of
surgery, the relative Fgf21 gene expressions were significantly
lower in the HF/HF and HF/CD groups after DJOS when
compared to SHAM (Figure 4(b), Tables 1 and 2).
3.6.2. DJOS Surgery. TheFgf21 gene expressions in the liver of
animals kept on HF/HF and mixed dietary patterns (HF/CD
8 BioMed Research International
Vertical lines depict 95% conﬁdence interval
FG
F 
21
 [p
g/
m
l]
0
100
200
300
400
500
600
700
800
900
1000
HF/HF HF/CD CD/HF CD/CD
DJOS
SHAM
(a)
FG
F 
21
 fo
ld
 ch
an
ge
Vertical lines depict 95% conﬁdence interval
0
1
2
3
4
5
6
7
HF/HF HF/CD CD/HF CD/CD
DJOS
SHAM
(b)
Figure 4: (a) Mean values of FGF 21 plasma levels in groups of diet, according to the DJOS and SHAM operation type. Statistical significance
was set at p < 0.05. Abbreviations: DJOS: duodenal-jejunal omega switch surgery; HF: high-fat diet; CD: control diet; HF/HF, CD/HF, HF/CD,
and CD/CD: type of diet 8 weeks before/8 weeks after surgery. (b) Mean values of Fgf21 fold change in groups of different dietary patterns,
according to the DJOS and SHAM operation type.
and CD/HF) were significantly higher as compared to the
CD/CD group (Figure 4(b), Tables 1 and 2).
3.6.3. SHAM Surgery. The CD/CD group showed signifi-
cantly lower Fgf21 gene expression in comparison with the
HF/HF, HF/CD, and CD/HF groups. Significant differences
were also observed between the HF/HF vs. CD/HF and
HF/CD vs. CD/HF groups (Figure 4(b), Tables 1 and 2).
4. Discussion
To better understand themetabolic changes under the condi-
tions of obesity, we have here analyzed selected hepatokines
in relation to different dietary patterns in combination with
duodenal exclusion. In this study, we present the effects of
HF and CD in combination with DJOS on plasma con-
centrations of RBP4, fetuin-A, and FGF21 as well as their
mRNA expression in the liver. We can state the following:
(i) Both diet and surgery strongly influenced plasma levels
of selected hepatokines. A reducing impact of DJOS surgery
on plasma levels of RBP4, fetuin-A, and FGF21 was detected.
(ii) Regardless of surgery, the type of dietary pattern applied
before and after the surgery had an impact on RBP4, fetuin-
A, and FGF21 plasma levels. Taking into consideration the
type of diet, comparing DJOS and SHAM, similar changes
in RBP 4, fetuin-A, and FGF21 plasma levels were observed.
(iii) The highest levels of RBP 4 and fetuin-A, but not FGF21,
were detected in the plasma of animals handled onHF before
and after the surgery in comparison to other groups; thus
HF has a reductive impact on the beneficial effect of DJOS
surgery. (iv) The lowest levels of RBP4 and fetuin-A were
characteristic for animals kept on a control diet before and
after the surgery. (v) DJOS surgery had a significant reductive
impact on relative gene expression of Rbp4, Ahsg, and Fgf21,
when compared to SHAM operated animals. (vi) Regardless
of the type of surgery, the type of dietary pattern applied
before and after the surgery influenced the relative gene
expression of selected hepatokines. HF used before and/or
after the surgery led to upregulation ofRbp4,Ahsg, and FGF21
relative gene expression when compared to the control.
DJOS surgery was shown to significantly decrease the
RBP4 plasma levels and Rbp4 expression level in the liver of
rats, regardless of diet used before or after surgery as com-
pared with SHAMoperated animals. Nevertheless, regardless
of the type of surgery, HF or mixed type of dietary pattern
stimulated Rbp4 expression and increased plasma concen-
tration of RBP4 when compared to the control diet. RBP4
is synthesized by hepatocytes and—to a lesser extent—by
adipocytes. It is responsible for retinol transport from the
liver to peripheral tissues [21]. Overexpression of Rbp4 in
adipocytes is reported in the conditions of insulin resistance,
metabolic syndrome, and obesity [7]. Our results are con-
sistent with other observations obtained on animals models,
which show that injection of RBP4 into mice or transgenic
overexpression of Rbp4 in mice leads to impaired insulin
signalling in the skeletal muscle tissue and influences the
activity of the gluconeogenic enzymes in the liver [22]. Wang
et al. observed upregulation of the Rbp4mRNA expression in
the liver and increasedRBP4 plasma concentrations inWistar
rats after 4 and 8weeks of high cholesterol diet, in comparison
with control group, and downregulation of Rbp4 mRNA
expression after 12 weeks of high cholesterol diet [23]. This
is probably the effect of rising RBP4 plasma concentration,
which may reduce the Rbp4 mRNA liver expression. Stefan
et al. observed that low hepatic fat content is correlated with
decreasedRBP4plasma levels andhigh insulin clearance [24].
In our previous study, a reduced content of fat in the liver
after DJOS surgery was observed in animals kept on HF/HF
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diet in comparison to SHAMoperated animals [19]. Based on
our results, we can suggest a strong relationship between the
plasma concentration of RBP4 and hepatic fat accumulation.
We observed a significant impact of DOJS surgery on the
RBP4 plasma levels and hepatic Rbp4 gene expression in all
dietary patterns applied. Similar results for different types of
bariatric surgery, butwithout involvement of dietary patterns,
were noticed after RYGB in proteomic study, where RBP4was
reduced up to 72% [25, 26].
Fetuin-A acts as an endogenous ligand for TLR4 which
stimulates adipose tissue inflammation and regulates insulin
sensitivity [27, 28]. The role of fetuin-A in the pathophysi-
ology of insulin resistance in rodents was proved by studies
conducted on Ahsg knockout mice (KO) [29]. The fetuin-A
KO animals showed increased insulin signalling, sensitivity,
and resistance to weight gain to the adipogenic effect of
the HF. Remarkably, KO mice fed with HF remained lean,
with body weight comparable to the control group [29].
Human studies show that fetuin-A plasma levels correlate
positively with the liver fat accumulation in nondiabetic
individuals, while Ahsg mRNA expression is upregulated in
hepatic dysfunction [30]. In a rat model of diet-induced
obesity, which commonly displays fatty liver, an upregulation
in Ahsg mRNA expression was also observed in the liver [12].
As mentioned above, a reduced fat content in the liver of
HF/HF DJOS operated animals was observed as compared
with HF/HF SHAM operated animals [19]. In that study,
we have shown that the fetuin-A plasma level and the Ahsg
mRNA expression in the liver are lower in animals after DJOS
surgery as compared with SHAM groups, regardless of the
dietary pattern. Any use ofHF such asHF/HF,mixedHF/CD,
and CD/HF stimulated the fetuin-A plasma concentrations
and triggered the mRNA expression in the liver tissue as
compared with the control diet. T2DM, as a comorbidity of
obesity, is a very complex disease, where the gene expression
and development are triggered/regulated by a combination
of genetic, epigenetic, environmental, and lifestyle factors,
including diet [31]. Despite the fact that T2DM is known to be
a highly heritable disease, only 10% to 15% of the heritability
of the disease is explained by known genetic mechanisms
[32].
It is known that FGF 21 is one of the main factors
involved in the pathogenesis and therapeutic mechanisms
of NAFLD [33]. FGF21 is upregulated by the nutrient sen-
sor, SIRT1, which ameliorates hepatic IR in diabetic obese
mice through suppression of mTORC1 [34]. The studies
conducted in vivo and in vitro prove that FGF21 inhibits
nutrient- and hormonal-induced hepatic mTORC1 activity.
During starvation FGF21 may be induced by activation of
TORC1 stimulated by TSC1 deficiency. Under this conditions
FGF21 acts in an autocrine fashion regulating liver fatty
acid metabolism, promoting glucose utilization, and control-
ling peripheral glucose homeostasis by stimulating hepatic
glycogen storage [34, 35]. Diet-induced obese, genetically
obese, diabetic db/db and ob/ob mice were shown to have
increased endogenous levels of FGF21 [36, 37]. Also, Fgf21
expression was increased in the liver of ob/ob mice when
compared to lean littermates [38]. These data led to the
hypothesis that increased plasma FGF21 levels may be a
prognostic factor of metabolic syndrome and T2DM and
that these may be states of relative FGF21-resistance [37].
In the present study, we show that the FGF21 plasma level
was lowered after DJOS surgery in comparison with SHAM
groups, even after long-term consumption of HF. Similar
results, but not related to the diet, were observed in human
studies after laparoscopic sleeve gastrectomy, where FGF21
plasma levels in obese subjects were significantly higher in
comparison to the control and decreased 12 and 24 months
after the surgery [39]. Here, the DJOS surgery reduced
the possible deleterious impact of HF, which was observed
in SHAM operated animals in the HF/HF, HF/CD, and
CD/HF groups, where FGF21 plasma levels and Fgf21 gene
expression were upregulated. Again the lowest values of this
protein were observed after DJOS surgery in the CD/CD
group. Other studies have shown that a very low-calorie diet
applied for two weeks increased the FGF21 plasma levels in
obese patients with T2DM [40]. Food restriction and low
caloric diet appear to enhance hepatic FGF21 production,
which helps to facilitate the physiological response to energy
deficiency by reduction of gluconeogenesis and increase of
hepatic ketogenesis via FGF21 [41]. Nonetheless, the plasma
concentration of FGF21 is also known to be elevated under
conditions of metabolic dysfunction, such as obesity [40].
Our present results may explain an influence of DJOS surgery
on the normalisation of the FGF21 sensitivity, which has been
reported to be highly reduced under obesity conditions [35].
Downregulation of the Fgf21 mRNA expression after DJOS
surgery may also suggest amelioration in the liver metabolic
functions, since the livermay be responsible for the rise of the
plasma FGF21 levels during overfeeding.
5. Conclusions
The efficiency of the DJOS surgery, measured by hepatokines’
plasma levels and their gene expressions in the liver, depends
on the type of diet applied before and after the surgery. HF,
despite the combination (HF/HF, HF/CD, and CD/HF) used
before and/or after surgery, showed a deleterious impact,
reducing the effect of the surgery. These data demonstrate
that manipulation of dietary patterns can lead to marked
improvements in metabolic profile after DJOS surgery.
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